Cargando…

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models

Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor for treating chronic lymphocytic leukemia (CLL). It has also been associated with hypertension. The optimal dosing schedule for mitigating this adverse effect is currently under discussion. A quantification of relationships between systemic ibrut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Eman I. K., Karlsson, Mats O., Friberg, Lena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508536/
https://www.ncbi.nlm.nih.gov/pubmed/37452622
http://dx.doi.org/10.1002/psp4.13010